- Home
- ENGN vs CDXC Comparison
ENGN vs CDXC Comparison
Compare ENGN & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- CDXC
- Stock Information
- Founded
- ENGN 1999
- CDXC 1999
- Country
- ENGN Canada
- CDXC United States
- Employees
- ENGN N/A
- CDXC N/A
- Industry
- ENGN
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- ENGN
- CDXC Health Care
- Exchange
- ENGN Nasdaq
- CDXC Nasdaq
- Market Cap
- ENGN 293.1M
- CDXC 264.4M
- IPO Year
- ENGN N/A
- CDXC N/A
- Fundamental
- Price
- ENGN $8.39
- CDXC $6.67
- Analyst Decision
- ENGN Strong Buy
- CDXC Strong Buy
- Analyst Count
- ENGN 6
- CDXC 2
- Target Price
- ENGN $33.67
- CDXC $8.00
- AVG Volume (30 Days)
- ENGN 128.7K
- CDXC 2.5M
- Earning Date
- ENGN 09-10-2024
- CDXC 10-31-2024
- Dividend Yield
- ENGN N/A
- CDXC N/A
- EPS Growth
- ENGN N/A
- CDXC N/A
- EPS
- ENGN N/A
- CDXC 0.02
- Revenue
- ENGN N/A
- CDXC $91,668,000.00
- Revenue This Year
- ENGN N/A
- CDXC $15.33
- Revenue Next Year
- ENGN N/A
- CDXC $20.08
- P/E Ratio
- ENGN N/A
- CDXC $344.07
- Revenue Growth
- ENGN N/A
- CDXC 9.95
- 52 Week Low
- ENGN $4.42
- CDXC $1.32
- 52 Week High
- ENGN $18.40
- CDXC $7.08
- Technical
- Relative Strength Index (RSI)
- ENGN 51.13
- CDXC 81.24
- Support Level
- ENGN $8.50
- CDXC $3.39
- Resistance Level
- ENGN $9.06
- CDXC $7.08
- Average True Range (ATR)
- ENGN 0.71
- CDXC 0.46
- MACD
- ENGN -0.12
- CDXC 0.36
- Stochastic Oscillator
- ENGN 1.02
- CDXC 90.06
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.